Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 701 to 750 of 4090 results for patient

  1. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.

  2. Baricitinib for treating moderate to severe atopic dermatitis (TA681)

    Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.

  3. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  4. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

    Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

  5. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  6. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.

  7. Varenicline for smoking cessation (TA123)

    Evidence-based recommendations on varenicline (Champix) for adults who want to stop smoking.

  8. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

    Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.

  9. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

  10. Irreversible electroporation for treating renal cancer (HTG303)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

  11. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

  12. Infracoccygeal sacropexy using mesh to repair uterine prolapse (HTG443)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the uterus in place.

  13. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  14. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.

  15. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  16. Trabecular stent bypass microsurgery for open-angle glaucoma (HTG432)

    Evidence-based recommendations on trabecular stent bypass microsurgery for open-angle glaucoma. This involves inserting a hollow metal tube (stent) into the eye, to improve drainage of fluid from the eye.

  17. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

  18. Bladder cancer (QS106)

    This quality standard covers diagnosing and managing bladder cancer in adults (aged 18 and over) referred from primary care. It describes high-quality care in priority areas for improvement.

  19. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  20. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

    Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.

  21. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  22. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

  23. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

  24. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

  25. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.

  26. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  27. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.

  28. HumiGard for preventing inadvertent perioperative hypothermia (HTG428)

    Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia.

  29. Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

    Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.

  30. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (HTG337)

    Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.

  31. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

  32. The Debrisoft monofilament debridement pad for use in acute or chronic wounds (HTG334)

    Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.

  33. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  34. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

  35. Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

    Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.

  36. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

  37. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

    Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.

  38. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

    Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  39. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (HTG593)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.

  40. Irreversible electroporation for primary liver cancer (HTG532)

    Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.

  41. Bronchoscopic thermal vapour ablation for upper-lobe emphysema (HTG517)

    Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults. This involves using steam to destroy the diseased part of the lung.

  42. Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.

  43. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (HTG450)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

  44. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

    Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.

  45. Commercial access agreements

    The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.